Here’s a startling fact: species that rapidly evolved in body size, like the Greater Kudu and Big Horn Sheep, actually have fewer cancerous tumors. But here’s where it gets controversial—this isn’t the case for non-cancerous tumors, leaving scientists to wonder why evolution seems to favor defenses against cancer in some instances but not others. New research from University College London and the University of Reading sheds light on this intriguing paradox, suggesting that rapid evolutionary changes in body size may have inadvertently fortified these animals against cancer, while benign tumors slipped under the radar of natural selection.
Published in the journal PNAS, this study builds on earlier work that challenged the long-held belief that larger animals, like elephants, are more prone to cancer than smaller ones, such as mice. While the new findings confirm that body size does increase tumor prevalence, they also reveal a fascinating twist: species that evolved quickly in size seem to have developed stronger anti-cancer mechanisms. And this is the part most people miss—it’s not just about size; it’s about the pace of evolutionary change.
Professor Chris Venditti, senior author of the research, emphasizes that cancer isn’t just a medical issue—it’s an ecological and evolutionary puzzle. By studying how tumors emerge and persist across species, researchers are uncovering the evolutionary pressures that shape cancer’s biology. For instance, benign tumors faced little evolutionary pressure to be controlled, while cancerous ones triggered stronger defenses in rapidly evolving species. This insight could revolutionize how we approach human cancer research and treatment resistance.
But not all species follow the same rules. Birds, for example, tell a different story. The study found that bird lineages that evolved quickly into new species had higher rates of both cancerous and non-cancerous tumors. Why? Birds have smaller, more compact genomes compared to mammals, which may make them more susceptible to genetic changes that promote tumors. Dr. George Butler, lead author of the research, points out that evolution leaves its mark even on diseases like cancer. Rapid evolution in body size seems to help species evade cancer, but it’s a double-edged sword—genetic shuffling that drives speciation can also lead to vulnerabilities, as seen in human prostate cancer where gene fusions drive aggressive disease.
Here’s a thought-provoking question for you: If rapid evolution can both protect against and increase susceptibility to cancer, what does this mean for our understanding of human cancer? Could studying these evolutionary patterns lead to breakthroughs in treatment? And are birds’ compact genomes a weakness or just a trade-off for their unique adaptations? Let’s discuss in the comments—your perspective could spark the next big idea in cancer research.
